Navigating Between Front-line Systemic Therapies in uHCC.

James J. Harding, MD, compares the responses observed with nivolumab plus ipilimumab (NIVO + IPI) therapy in the CheckMate 9DW trial to other first-line (1L) immunotherapy (IO) regimens for unresectable hepatocellular carcinoma (uHCC), including the HIMALAYA 5-year update (STRIDE) and the IMbrave150 trial (atezolizumab [ATEZO] + bevacizumab [BEV]), highlighting differences in efficacy and treatment outcomes.

EP: 1.Evolving First-Line Treatment Strategies for uHCC.

EP: 2.An Introduction to Front-line Nivolumab/Ipilimumab Therapy for uHCC: The CheckMate 9DW Study.

EP: 3.Academic Perspectives on Front-line Nivolumab/ Ipilimumab Therapy for uHCC.

Now Viewing

EP: 4.Navigating Between Front-line Systemic Therapies in uHCC.

Video content above is prompted by the following:

• Consider the other 1L systemic therapies in uHCC. How do the responses with NIVO + IPI therapy in CheckMate 9DW compare with other 1L IO regimens? HIMALAYA 5-year update (STRIDE), Rimassa et al, ESMO 2024 and IMbrave150 (ATEZO + BEV), Cheng et al, J Hepatol 2022.

Recent Videos